JQDN

General

The Value Of Cintec® Plus Cytology Test In Cervical Cancer

Di: Stella

Roche’s CINtec PLUS Cytology is the only FDA-approved and CE-marked dual-stain test to triage human papillomavirus (HPV)-positive cervical cancer screening test results

Updated American Society of Colposcopy and Cervical Pathology (ASCCP) guidelines recognize the importance of dual-stain biomarkers in managing early diagnosis of HPV- positive cervical

CINtec® PLUS Cytology Kit, CE-IVD

Cervical cancer (CC) is a type of cancer with poor prognosis when diagnosed in advanced stage with a big socioeconomic burden. The incidence rates have wide variations More accurate biomarkers in cervical cytology screening could reduce the number of women biomarker technology unnecessarily referred for biopsy. This study investigated the ability of p16/Ki-67 dual The FDA has approved the expanded use of the CINtec PLUS Cytology assay for women who undergo cervical cancer screening and test positive for high-risk types of human

New Paradigms in Cervical Cancer Prevention

Abstract Cervical cancer screening saves lives. Secondary prevention in cervical cancer screening relies on the results of primary cytology and/or HPV testing. However, primary Roche has received an expanded the US Food and Drug Administration (FDA) approval for CINtec PLUS Cytology, a triage test that leverages biomarker technology. The A Budget Impact Model (BIM) was created based [8] on a Markov decision-analytic model in order to calculate the budget impact of primary HPV screening with dual-stain

These were cytology negative for intra-epithelial neoplasia (NILM) and a positive HPV test. Prognostic value of the CINtec PLUS test for NILM samples and the confounding effect of Xpert HPV HPV Roche’ s CINtec PLUS Cytology is the only FDA- approved and CE-marked dual-stain test to triage human papillomavirus- positive cervical cancer screening test results Dual

Abstract Background CINtec ® PLUS p16/Ki-67 dual-stained cytology (DS) is an alternative test to cytology in triaging human papillomavirus (HPV)-positive women. Dalton p16/Ki-67 Dual Stain About cobas Systems cobas HPV tests run on cobas Systems and are indicated for use for routine cervical cancer screening to assess the risk in women for cervical precancer

CINtec PLUS Cytology has high sensitivity for the prediction of high-grade cervical lesions. A positive result identifies patients who are more likely to harbour high-grade lesions and would This means that either cancers are missed, or women are over-treated. To improve performance outcomes, the concept of dual-stain cytology (CINtec® PLUS Cytology test) has been The CINtec PLUS Cytology Kit is an immunocytochemistry assay for the simultaneous qualitative detection of the p16INK4a and Ki-67 proteins in cervical cytology preparations. It is indicated to be used as an aid in the identification of

The FDA has approved the expanded use of CINtec PLUS Cytology, the first triage test based on biomarker technology for women whose cervical cancer screening results are positive for high-risk types of human “Adding dual-stain cytology to the WHO guidelines further reinforces the value of our biomarker-based CINtec PLUS Cytology test to identify patients with an elevated risk of

The updated ASCCP guidelines now address the use of dual-stain technology for cervical cancer screening relies on management. CINtec PLUS Cytology is a test for the co-expression of p16 and Ki67 and

CINtec Plus cytology is the first biomarker-based triage test for women whose primary cervical cancer screening results are positive for HPV. 4. Determine the relationship between the cytology PAP test results and the Cintec Plus test results. 5. To evaluate the relationship between HPV DNA and Cintec Plus test results for

Roche’s CINtec PLUS Cytology is the only FDA-approved and CE-marked dual-stain test to triage human papillomavirus (HPV)-positive cervical cancer screening test results

Roche’s CINtec PLUS Cytology is the only FDA-approved and CE-marked dual-stain test to triage human papillomavirus (HPV)-positive cervical cancer screening test results

The test of CINTEC plus cytology has been introduced which combines both morphology and presence of P16 and Ki-67 in the same smear which gives an immediate

To improve performance outcomes, the concept of dual-stain cytology (CINtec ® PLUS Cytology test) has been introduced. In this approach, additional staining with p16/Ki-67 Each woman provided both cervical and vaginal specimens that were tested for high-risk human papillomavirus Adding dual (hrHPV) DNA using the Xpert HPV Test (Cepheid) at point of care. A subset of This study aims to investigate the prognostic value of the CINtec PLUS test in women with NILM cytology and HPV-positivity and its possible clinical implementation in the current screening

Roche’s CINtec PLUS Cytology is the only FDA-approved and CE-marked dual-stain test to triage human papillomavirus (HPV)-positive cervical cancer screening test results INTENDED USE The CINtec® PLUS Cytology test is a qualitative immunocytochemical assay intended for the simultaneous detection of the p16INK4a and Ki-67 proteins in cervical

Roche’s CINtec PLUS Cytology is the only FDA-approved and CE-marked dual-stain test to triage human papillomavirus (HPV)-positive cervical cancer screening test results However, not every HPV-positive woman will develop cervical cancer, and CINTec PLUS Cytology triage can determine a patient’s individual risk level and if they would benefit Roche’s CINtec PLUS Cytology is the only FDA-approved and CE-marked dual-stain test to triage human papillomavirus (HPV)-positive cervical cancer screening test results